Ensign Peak Advisors Inc Buys New Position in Doximity, Inc. (NASDAQ:DOCS)

Ensign Peak Advisors Inc bought a new stake in Doximity, Inc. (NASDAQ:DOCS – Get Rating) during the 3rd quarter, Holdings Channel.com reports. The firm bought 22,027 shares of the company’s stock, valued at approximately $666,000.

Several other institutional investors have also added to or reduced their stakes in the stock. First Trust Advisors LP boosted its holdings in Doximity by 308.9% in the third quarter. First Trust Advisors LP now owns 197,886 shares of the company’s stock valued at $5,980,000 after acquiring an additional 149,487 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Doximity by 17.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 428,680 shares of the company’s stock worth $12,955,000 after buying an additional 63,615 shares in the last quarter. Bellevue Group AG boosted its holdings in shares of Doximity by 41.9% during the 3rd quarter. Bellevue Group AG now owns 193,439 shares of the company’s stock worth $5,846,000 after buying an additional 57,117 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Doximity by 70.8% during the 3rd quarter. BlackRock Inc. now owns 8,905,675 shares of the company’s stock worth $269,130,000 after buying an additional 3,693,016 shares in the last quarter. Finally, Capital Fund Management S.A. bought a new position in shares of Doximity during the 3rd quarter worth approximately $2,727,000. 52.48% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on DOCS. Morgan Stanley cut Doximity from an “equal weight” rating to an “underweight” rating and cut their price target for the stock from $32.00 to $29.00 in a report on Friday, January 6th. Piper Sandler increased their price target on Doximity from $35.00 to $38.00 in a report on Friday, February 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $45.00 target price on shares of Doximity in a research report on Friday, February 10th. JPMorgan Chase & Co. lowered their target price on Doximity from $60.00 to $30.00 and set an “underweight” rating on the stock in a research report on Friday, February 17th. Finally, Canaccord Genuity Group lowered their target price on Doximity from $42.00 to $41.00 and set a “buy” rating on the stock in a research report on Friday, February 10th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $40.50.

Doximity Price Performance

Shares of NASDAQ:DOCS opened at $29.08 on Tuesday. The company has a market capitalization of $5.63 billion, a PE ratio of 52.87, a price-to-earnings-growth ratio of 15.32 and a beta of 0.87. The business has a fifty day moving average price of $33.59 and a two-hundred day moving average price of $31.96. Doximity, Inc. has a 1 year low of $22.91 and a 1 year high of $54.69.

Insider Buying and Selling at Doximity

In other Doximity news, CFO Anna Bryson sold 25,000 shares of the company’s stock in a transaction on Thursday, February 2nd. The stock was sold at an average price of $40.00, for a total value of $1,000,000.00. Following the completion of the transaction, the chief financial officer now owns 104,763 shares in the company, valued at approximately $4,190,520. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 45.21% of the company’s stock.

Doximity Company Profile

(Get Rating)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.